PremiumRatingsPromising Outlook for Tenaya Therapeutics: Buy Rating Justified by Innovative Gene Therapy Potential Tenaya announces interim data from ongoing RIDGE study Promising Outlook for Tenaya Therapeutics: Buy Rating Backed by Strategic Advantages and Market Opportunities PremiumThe FlyTenaya data further builds TN-201 profile, says H.C. Wainwright Promising Developments in Tenaya Therapeutics’ Gene Therapy Trials Bolster Buy Rating Tenaya says TN-201 well tolerated in Phase 1b/2 interim data PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Promising Clinical Data and Financial Stability Support Buy Rating for Tenaya Therapeutics Despite Price Target Reduction Tenaya Therapeutics price target lowered to $6 from $18 at Canaccord 
